- Home
- VITL vs FBRX Comparison
VITL vs FBRX Comparison
Compare VITL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VITL | FBRX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.5M | 487.2M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VITL | FBRX |
|---|---|---|
| Price | $12.71 | $20.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $32.00 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 2.5M | 375.9K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.03 | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $759,444,000.00 | $36,000.00 |
| Revenue This Year | $19.72 | N/A |
| Revenue Next Year | $17.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $7.95 | $9.12 |
| 52 Week High | $53.13 | $35.80 |
Technical Indicators
Market Signals| Indicator | VITL | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.89 | 56.37 |
| Support Level | $12.09 | $16.58 |
| Resistance Level | $13.47 | $22.84 |
| Average True Range (ATR) | 0.66 | 1.44 |
| MACD | 0.25 | 0.70 |
| Stochastic Oscillator | 89.84 | 73.34 |
Price Performance
Historical ComparisonAbout VITL Vital Farms Inc.
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.